Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 3/2009

01-03-2009 | Original Paper

Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection

Authors: Yi-Wei Li, Shuang-Jian Qiu, Jia Fan, Qiang Gao, Jian Zhou, Yong-Sheng Xiao, Yang Xu, Xiao-Ying Wang, Jian Sun, Xiao-Wu Huang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2009

Login to get access

Abstract

Purpose

To evaluate the prognostic value of tumor-associated macrophages (TAM), individually or synergistically with CD45RO + memory T cells (TM), in hepatocellular carcinoma (HCC) patients following resection.

Methods

The infiltration of TAM and TM was assessed by immunohistochemistry in tissue microarray containing 302 HCC specimens. Correlations between TAM/TM infiltration and clinicopathologic features, disease-free survival (DFS) and overall survival (OS) were statistically analyzed.

Results

High TAM infiltration was associated with both improved DFS (P = 0.0021) and OS (P = 0.0481). Multivariate analysis identified TAM infiltration as independent prognostic factor for DFS (P = 0.004) and OS (P = 0.049). A second analysis clarified the synergistic effect of TAM&TM infiltration for DFS (P = 0.004) and OS (P = 0.040).

Conclusions

Both TAM infiltration alone and concomitant infiltration of TAM&TM are associated with improved DFS/OS, suggesting that TAM could protect HCC patients from recurrence/metastasis and prolong survival by distinct mechanisms.
Appendix
Available only for authorised users
Literature
Abe K, Harada M, Tamada K et al (1998) Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol Immunother 45:225–233PubMedCrossRef
Blankenstein T, Qin ZH, Uberla K et al (1991) Tumor suppression after tumor cell targeted tumor necrosis factor α gene transfer. J Exp Med 173:1047–1052PubMedCrossRef
Bolat F, Kayaselcuk F, Nursal TZ et al (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 25:365–372PubMed
Bonta IL, Ben-Efraim S (1993) Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 54:613–626PubMed
Bortolami M, Venturi C, Giacomelli L et al (2002) Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis 34:794–801PubMedCrossRef
Brigati C, Noonan DM, Albini A et al (2002) Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 19:247–258PubMedCrossRef
Budhu A, Forgues M, Ye QH et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99–111PubMedCrossRef
Cai XY, Gao Q, Qiu SJ et al (2006) Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 132:293–301PubMedCrossRef
Chu CS, Woo EY, Toll AJ et al (2002) Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. Clin Immunol 102:291–301PubMedCrossRef
De Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37PubMedCrossRef
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148PubMedCrossRef
Forssell J, Oberg A, Henriksson ML et al (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13:1472–1479PubMedCrossRef
Galarneau H, Villeneuve J, Gowing G et al (2007) Increased glioma growth in mice depleted of macrophages. Cancer Res 67:8874–8881PubMedCrossRef
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef
Gao Q, Qiu SJ, Fan J et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586–2593PubMedCrossRef
Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP- 9–expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623–633PubMed
Hock H, Dorsch M, Kunzendorf U et al (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 90:2774–2778PubMedCrossRef
Jewell AP (2005) Is the liver an important site for the development of immune tolerance to tumors? Med Hypothesis 64:751–754CrossRef
Langrish CL, McKenzie BS, Wilson NJ et al (2004) IL–12 and IL–23: master regulators of innate and adaptive immunity. Immunol Rev 202:96–105PubMedCrossRef
Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66:605–612PubMedCrossRef
Lin CY, Lin CJ, Chen KH et al (2006) Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett 580:3042–3050PubMedCrossRef
Lissbrant IF, Stattin P, Wikstrom P et al (2000) Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17:445–451PubMed
Macmicking J, Xie QW, Nathan C (1997) Nitric oxide and macrophage function. Annu Rev Immunol 15:323–350PubMedCrossRef
Michie CA, McLean A, Alcock C et al (1992) Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360:264–265PubMedCrossRef
Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104:2224–2234PubMedCrossRef
Ohno S, Inagawa H, Dhar D et al (2003) The degree of macrophage infiltration into cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23:5015–5022PubMed
Ohno S, Inagawa H, Soma G et al (2002) Role of tumor-associated macrophage in malignant tumors: should the location of the infiltrated macrophages be taken into account during evaluation? Anticancer Res 22:4269–4275PubMed
Ohno S, Ohno Y, Suzuki N et al (2004) Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 24:3335–3342PubMed
Pages F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666PubMedCrossRef
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
Peng SH, Deng H, Yang JF et al (2005) Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol 11:6521–6524PubMed
Pollard JW (2004) Tumor-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71–78PubMedCrossRef
Prendergast GC, Jaffee EM (2007) Cancer immunologists and cancer biologists: why we didn’t talk then but need to now. Cancer Res 67:3500–3504PubMedCrossRef
Sica A, Schioppa T, Mantovani A et al (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42:717–727PubMedCrossRef
Taskinen M, Karjalainen-Lindsberg ML, Nyman H et al (2007) A high tumor- associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 13:5784–5789PubMedCrossRef
Tsutsui S, Yasuda K, Suzuki K et al (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14:425–431PubMed
Unitt E, Marshall A, Gelson W et al (2006) Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 45:246–253PubMedCrossRef
Varotti G, Ramacciato G, Ercolani G et al (2005) Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol 3:760–767CrossRef
Yakirevich E, Resnick MB (2007) Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol 25:2586–2593CrossRef
Metadata
Title
Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection
Authors
Yi-Wei Li
Shuang-Jian Qiu
Jia Fan
Qiang Gao
Jian Zhou
Yong-Sheng Xiao
Yang Xu
Xiao-Ying Wang
Jian Sun
Xiao-Wu Huang
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0469-0

Other articles of this Issue 3/2009

Journal of Cancer Research and Clinical Oncology 3/2009 Go to the issue

Original Paper

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines

Original Paper

Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer

Review

The possible involvement of virus in breast cancer

Rapid Communication

The prevalence of microsatellite instability in head and neck squamous cell carcinoma

Original Paper

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin’s lymphoma

Original Paper

A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits